Lyell Will Seek To Improve On Existing CAR-Ts Via Merger With ImmPACT

Lyell believes ImmPACT’s dual CD19/20-targeted CAR-T could offer better response rates than Yescarta or Breyanzi and will focus on IMPT-314 while terminating much of its own pipeline.